Mizuho Issues Positive Forecast for Lantheus (NASDAQ:LNTH) Stock Price

Lantheus (NASDAQ:LNTH) had its price target hoisted by Mizuho from $60.00 to $72.00 in a report issued on Wednesday,Benzinga reports. The brokerage presently has an “outperform” rating on the medical equipment provider’s stock. Mizuho’s price target would indicate a potential upside of 10.48% from the stock’s previous close.

Several other analysts also recently weighed in on LNTH. The Goldman Sachs Group set a $77.00 target price on shares of Lantheus and gave the company a “neutral” rating in a report on Wednesday, October 8th. TD Cowen lowered their price target on Lantheus from $95.00 to $80.00 and set a “buy” rating for the company in a research report on Monday, September 15th. B. Riley dropped their price objective on Lantheus from $109.00 to $84.00 and set a “buy” rating for the company in a research note on Tuesday, September 16th. Truist Financial set a $80.00 price objective on Lantheus and gave the company a “buy” rating in a report on Thursday, December 11th. Finally, Weiss Ratings cut Lantheus from a “hold (c-)” rating to a “sell (d+)” rating in a report on Saturday, October 25th. Five investment analysts have rated the stock with a Buy rating, two have given a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, Lantheus presently has a consensus rating of “Moderate Buy” and an average target price of $77.67.

Lantheus Trading Down 2.1%

NASDAQ LNTH opened at $65.17 on Wednesday. The company has a debt-to-equity ratio of 0.51, a current ratio of 2.67 and a quick ratio of 2.49. The stock has a market capitalization of $4.32 billion, a P/E ratio of 27.38 and a beta of -0.10. The firm’s 50-day moving average is $57.11 and its two-hundred day moving average is $62.88. Lantheus has a 12 month low of $47.25 and a 12 month high of $111.29.

Lantheus (NASDAQ:LNTH) last announced its quarterly earnings results on Tuesday, May 17th. The medical equipment provider reported $0.05 earnings per share for the quarter. The business had revenue of $92.51 million during the quarter. Lantheus had a net margin of 10.99% and a return on equity of 30.88%. On average, sell-side analysts anticipate that Lantheus will post 6.01 earnings per share for the current year.

Institutional Trading of Lantheus

Hedge funds have recently modified their holdings of the stock. Hantz Financial Services Inc. grew its stake in Lantheus by 412.5% during the 3rd quarter. Hantz Financial Services Inc. now owns 492 shares of the medical equipment provider’s stock worth $25,000 after purchasing an additional 396 shares in the last quarter. Elevation Point Wealth Partners LLC acquired a new stake in Lantheus in the 2nd quarter valued at about $26,000. First Horizon Corp purchased a new position in shares of Lantheus in the 3rd quarter valued at about $26,000. Osterweis Capital Management Inc. acquired a new position in shares of Lantheus during the second quarter worth about $36,000. Finally, Quarry LP grew its position in shares of Lantheus by 2,350.0% during the first quarter. Quarry LP now owns 490 shares of the medical equipment provider’s stock worth $48,000 after buying an additional 470 shares in the last quarter. 99.06% of the stock is currently owned by institutional investors and hedge funds.

About Lantheus

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.